Bio Essence reported a sharp revenue rebound to $1.898 million in 2025, driven by increased OEM service volume, with basic and diluted net income per share of $0.02 reflecting a return to profitability. The improvement in top-line sales and higher gross margins on OEM services contributed to operating income of $900,011 and net income of $896,197 for the year. These results follow a strategic shift away from in‑house product sales toward outsourced OEM manufacturing services.

Financial Highlights

• Total revenues: $1.898 million (up from $0.324 million in 2024)
• Gross profit: $1.428 million (up from $0.217 million in 2024)
• Income (loss) from operations: $900,011 (compared to $(459,438) in 2024)
• Net income (loss): $896,197 (compared to $(1,308,796) in 2024)
• Basic and diluted net income per share: $0.02 (compared to $(0.03) per share in 2024)

Business Highlights

• Revenue growth driver: Revenue surged approximately 486% to $1.90M in 2025, primarily from large OEM service orders from three new major clients.
• Channel shift: The company executed a strategic pivot from product sales to providing OEM manufacturing services; product sales declined to nil in 2025.
• Operational outsourcing: Following the sale of BEP and BEH, the company now outsources manufacturing and OEM operations rather than conducting in‑house production.
• Cost and margin momentum: As OEM services scaled, gross profit improved materially while the company maintained a controlled cost structure.
• R&D subsidiary status: McBE, an R&D/prescription drug focused subsidiary, was formed and later dissolved; the company remains concentrated on supplement OEM services.

Original SEC Filing: Bio Essence Corp [ BIOE ] - 10-K - Mar. 27, 2026